318 related articles for article (PubMed ID: 21713757)
61. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
[TBL] [Abstract][Full Text] [Related]
62. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
Zhou J; Roh JW; Bandyopadhyay S; Chen Z; Munkarah AR; Hussein Y; Alosh B; Jazaerly T; Hayek K; Semaan A; Sood AK; Ali-Fehmi R
Gynecol Oncol; 2013 Feb; 128(2):344-8. PubMed ID: 22871469
[TBL] [Abstract][Full Text] [Related]
63. High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer.
Jang SH; Lee JE; Oh MH; Lee JH; Cho HD; Kim KJ; Kim SY; Han SW; Kim HJ; Bae SB; Lee HJ
J Breast Cancer; 2016 Mar; 19(1):53-60. PubMed ID: 27066096
[TBL] [Abstract][Full Text] [Related]
64. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG
Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346
[TBL] [Abstract][Full Text] [Related]
65. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW; Choe M
Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
[TBL] [Abstract][Full Text] [Related]
66. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E; Bertucci F; Pierga JY; Petit T; Levy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; van Laere S; Ueno NT; Toiron Y; Finetti P; Birnbaum D; Borg JP; Viens P; Chinot O; Gonçalves A
Oncotarget; 2016 Apr; 7(14):18531-40. PubMed ID: 26921265
[TBL] [Abstract][Full Text] [Related]
67. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.
Meseure D; Vacher S; Alsibai KD; Nicolas A; Chemlali W; Caly M; Lidereau R; Pasmant E; Callens C; Bieche I
Mol Cancer Res; 2016 Jul; 14(7):623-33. PubMed ID: 27102007
[TBL] [Abstract][Full Text] [Related]
68. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
69. IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
Dawood S; Cristofanilli M
J Natl Cancer Inst Monogr; 2015 May; 2015(51):56-9. PubMed ID: 26063888
[TBL] [Abstract][Full Text] [Related]
70. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
[TBL] [Abstract][Full Text] [Related]
71. Preoperative Radiation Therapy for Chemorefractory Localized Inflammatory Breast Cancer.
Rogé M; Kirova Y; Loap P; Amar S; Servagi S; Nebbache R; Rivin Del Campo E; Clatot F; Thureau S; Thariat J
Pract Radiat Oncol; 2023; 13(6):e491-e498. PubMed ID: 37295726
[TBL] [Abstract][Full Text] [Related]
72. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
Bertucci F; Finetti P; Colpaert C; Mamessier E; Parizel M; Dirix L; Viens P; Birnbaum D; van Laere S
Oncotarget; 2015 May; 6(15):13506-19. PubMed ID: 25940795
[TBL] [Abstract][Full Text] [Related]
73. Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.
Johnson KC; Grimm M; Sukumar J; Schnell PM; Park KU; Stover DG; Jhawar SR; Gatti-Mays M; Wesolowski R; Williams N; Sardesai S; Pariser A; Sudheendra P; Tozbikian G; Ramaswamy B; Doto D; Cherian MA
Breast; 2023 Dec; 72():103591. PubMed ID: 37871527
[TBL] [Abstract][Full Text] [Related]
74. Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung.
Bondgaard AL; Poulsen TT; Poulsen HS; Skov BG
Cancer Biomark; 2012; 11(2-3):123-8. PubMed ID: 23011159
[TBL] [Abstract][Full Text] [Related]
75. Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007).
Zhou Q; Zhang HP; Zhao YT; Wang XH; Xiong W; Liu YJ; Zhang JH;
Chin Med J (Engl); 2020 Nov; 133(21):2552-2557. PubMed ID: 32925286
[TBL] [Abstract][Full Text] [Related]
76. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
77. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
Lacerda L; Reddy JP; Liu D; Larson R; Li L; Masuda H; Brewer T; Debeb BG; Xu W; Hortobágyi GN; Buchholz TA; Ueno NT; Woodward WA
Stem Cells Transl Med; 2014 Jul; 3(7):849-56. PubMed ID: 24833589
[TBL] [Abstract][Full Text] [Related]
78. EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response.
Gan Y; Lo Y; Makower D; Kleer C; Lu J; Fineberg S
Appl Immunohistochem Mol Morphol; 2022 Oct; 30(9):614-622. PubMed ID: 36048167
[TBL] [Abstract][Full Text] [Related]
79. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
[TBL] [Abstract][Full Text] [Related]
80. EZH2 expression in invasive lobular carcinoma of the breast.
Roh S; Park SY; Ko HS; Sohn JS; Cha EJ
World J Surg Oncol; 2013 Nov; 11():299. PubMed ID: 24266940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
